EVALUATION OF THE EFFICACY OF INTRAVENOUS VITAMIN C IN THE MANAGEMENT OF COVID 19 -A Prospective Randomized Controlled Trial - VCMC

I0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•All patients above the age of 18 years both males and females, admitted with a diagnosis of
•Moderate & Severe COVID -19 (on the basis of a positive RT-PCR report) at our facility during the
•study period (16/08/2020-15/12/2020)

•1. Patients with a known allergy to or adverse drug reaction with vitamin C.
•2. Patients unable to provide consent or unwilling to participate in the study.
•3. Patients participating in any other ongoing clinical trial will be excluded from the study.
•4. Patients below the age of 18 years will be excluded from the study.
•5. Pregnant or Breastfeeding Females will be excluded from the study.
•6.Patients previously complicated with End-stage Lung Disease, End stage Malignancy, Glucose-6-
•Phosphate dehydrogenase deficiency, Diabetes Mellitus & Diabetic Ketoacidosis , Nephrolithiasis,
•Chronic Kidney Disease, Cardiogenic Pulmonary Edema will be Excluded from the study.

发起方